Despite the promise of a new era of health care in which medicine has shifted from treating conditions to emphasizing prevention fueled by individualized care, a significant gap remains in realizing its benefits because of outmoded attitudes, protocols and procedures targeted for treating mass populations. Such is the core argument and motivation behind the “Personalized Health Manifesto,” released to kick off the 2010 Translational Medicine Alliance Forum (TMAF).

Written by journalist and best-selling author David Ewing Duncan and funded by the Ewing Marion Kauffman Foundation, the manifesto is “an old-fashioned call to arms and action plan for a new age of health care” that takes direct aim at the challenges of integrating and implementing personalized health care in the United States and seeks to accelerate the incorporation of personalized health into the current health care system.

The manifesto's “action plan” aims to set a new direction for health care, emphasizing prediction, prevention, individualized care and healthy wellness to ensure that the best medicines make it to the marketplace and optimize patient care. By focusing on the whole human organism, the manifesto challenges the prevailing use of drugs and protocols to target populations and averages rather than individuals. It further outlines the necessary groundwork for speeding up the process of moving from research to new drugs and other products and treatments by introducing more effective models that will ultimately improve health and reduce health care costs.

The manifesto was prepared with input from life science leaders representing medicine, business, government, patients, law and the media. Although the work is solely that of the author, these advisors have endorsed the manifesto, and many of them are convening at the TMAF today. The manifesto organizers hope to acquire the endorsement of at least 500 life science leaders by the end of the year.

To participate, add your name to the list of endorsers and leave comments here   

Read the names and comments of endorsers who have signed the Manifesto   

Expert Panel:

The following individuals participated in the development of the Personalized Health Manifesto and have endorsed it; neither they nor anyone else has had any editorial influence over this document.

ADAM GAZZALEY, MD, PhD, neurologist and neuroscientist, University of California at San Francisco
ANTHONY ATALA, MD, board member, Regenerative Medicine Foundation; director, Wake Forest Institute for Regenerative Medicine
ATUL BUTTE, MD, PhD, geneticist and bioinformaticist, Stanford University Medical School
BROOK BYERS, MBA, venture capitalist, Kleiner Perkins Caufield & Byers
CHRIS AUSTIN, MD, neurologist; director, Chemical Genomics Center, National Institutes of Health
DANIEL KRAFT, MD, PhD, oncologist; stem cell researcher, Stanford University Medical School
DAVID AGUS, MD, oncologist, proteomics researcher, entrepreneur, University of Southern California; co-founder, Navigenics
DAVID EWING DUNCAN, journalist and life science policy analyst; director, The Center for Life Science Policy, UC Berkeley
DIETRICH STEPHAN, PhD, geneticist; director, Ignite Institute; co-founder, Navigenics
EDWARD ABRAHAMS, PhD, president, Personalized Medicine Coalition
ERIC SCHADT, PhD, biocomputationist; chief scientific officer, Pacific Biosciences; co-founder, Sage Bionetworks
ERIC TOPOL, MD, cardiologist and translational geneticist; director, Scripps Translational Science Institute
FRANK DOUGLAS, MD, PhD, president and chief executive officer, Austen BioInnovation Institute of Akron, Ohio; founder and first executive director of the MIT Center for Biomedical Innovation, Massachusetts Institute of Technology; former chief scientific officer, Aventis
FRED FRANK, MBA, life sciences investment banker; vice chairman, Peter J. Solomon Company; former vice chairman, Lehman Brothers
GEORGE CHURCH, PhD, molecular biologist, professor of Genetics, and director, Center for Computational Genetics, Harvard Medical School
GEORGE POSTE, PhD, researcher, policy analyst, and former pharmaceutical executive; chief scientist, Complex Adaptive Systems Initiative and professor of Health Innovation, Arizona State University; former president, R&D, of SmithKline Beecham
GREG SIMON, JD, senior vice president for Worldwide Policy, Pfizer; former president, FasterCures; former chief domestic policy advisor to Vice President Al Gore
GREGORY STOCK, PhD, MBA, founding CEO, Signum Biosciences; founding director, Program on Medicine, Technology and Society, University of California at Los Angeles School of Medicine
HANK GREELY, JD, professor of Law, Stanford University; director, Center for Law and the Biosciences
JAMES HEYWOOD, co-founder and chairman, PatientsLikeMe
JAMES THOMSON, VMD, PhD, stem cell scientist; director of Regenerative Biology, The Morgridge Institute for Research, University of Wisconsin School of Medicine and Public Health
JOSHUA ADLER, MD, physician, chief medical officer, University of California at San Francisco Medical Center
LEE HOOD, MD, PhD, molecular biologist and bioinformaticist; founder and director, Institute for Systems Biology
LINDA K. MOLINAR, PhD, entrepreneur, personalized medicine and nanotechnology expert; founding principal, LKM Strategic Consulting
MARGARET ANDERSON, executive director, FasterCures
MARTYN SMITH, PhD, professor of Toxicology, School of Public Health, Division of Environmental Health Sciences, University of California Berkeley
MICHAEL ROIZEN, MD, preventive medicine; director, Wellness Institute, Cleveland Clinic
MISHA ANGRIST, PhD, assistant professor, Duke University Institute for Genome Sciences & Policy
NATHANIEL DAVID, PhD, entrepreneur and venture capitalist; venture partner, Arch Venture Partners
PAUL BILLINGS, MD, PhD, clinical geneticist; director, Genomic Medicine Institute, El Camino Hospital
RAY WOOSLEY, MD, PhD, president and CEO, Critical Path Institute
SAFI BAHCALL, PhD, entrepreneur; CEO, Synta Pharmaceuticals Corp
STEPHEN FRIEND, MD, PhD, president, CEO, co-founder, Sage Bionetworks; former senior vice president and franchise head for Oncology Research, Merck
STEPHEN SPIELBERG, MD, PhD, pediatrician; director, Center for Personalized Medicine and Therapeutic Innovation, Children's Mercy Hospital, Kansas City, Missouri; former dean, Dartmouth Medical School
STEVE WIGGINS, venture capitalist and former health insurance executive; managing director of Essex Woodlands Health Ventures; founder and former CEO, Oxford Health Plans
ZACK LYNCH, executive director, Neurological Industry Organization